TG Therapeutics
TGTX
181 hedge funds and large institutions have $965M invested in TG Therapeutics in 2022 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 74 increasing their positions, 47 reducing their positions, and 43 closing their positions.
57% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 47
27% more call options, than puts
Call options by funds: $28M | Put options by funds: $22.1M
0.56% more ownership
Funds ownership: 70.16% → 70.72% (+0.56%)
7% less funds holding
Funds holding: 194 → 181 (-13)
28% less first-time investments, than exits
New positions opened: 31 | Existing positions closed: 43
49% less capital invested
Capital invested by funds: $1.91B → $965M (-$942M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$44M |
| 2 |
Millennium Management
New York
|
+$19M |
| 3 |
6CM
683 Capital Management
New York
|
+$16.1M |
| 4 |
AC
Antara Capital
New York
|
+$12M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$12M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$79.3M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$42M |
| 3 |
LPC
Lion Point Capital
New York
|
-$22M |
| 4 |
HRCM
Hood River Capital Management
Palm Beach Gardens,
Florida
|
-$18.3M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$15.3M |
TGTX Hedge Fund Activity: Q1 2022 in Review
181 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q1 2022, worth a combined $965M — down 49% from $1.91B a quarter earlier.
Sellers outnumbered buyers: 43 funds closed out of TGTX and 31 opened new positions — a net loss of 12 holders — while 47 trimmed existing stakes and 74 added.
The largest buyer was State Street, adding an estimated $44M. The largest seller was Capital World Investors, exiting entirely with an estimated $79.3M sold.
- 181 institutional investors held TG Therapeutics (TGTX) as of Q1 2022, down from 194 in Q4 2021.
- Funds reported $965M of TG Therapeutics stock for Q1 2022, down 49% quarter-over-quarter.
- 31 funds opened new TG Therapeutics positions in Q1 2022 and 43 closed out, a net change of -12 holders.
- The largest TG Therapeutics buyer in Q1 2022 was State Street, an estimated $44M added.
- The largest TG Therapeutics seller in Q1 2022 was Capital World Investors, an estimated $79.3M sold.
Based on aggregated 13F filings for Q1 2022.